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Abstract
Lower than normal levels of oxygen (hypoxia) is a hallmark of all solid tumours rendering them frequently resistant
to both radiotherapy and chemotherapy regimes. Furthermore, tumour hypoxia and activation of the hypoxia
inducible factor (HIF) transcriptional pathway is associated with poorer prognosis. Driven by both genetic and
epigenetic changes, cancer cells do not only survive but thrive in hypoxic conditions. Detailed knowledge of these
changes and their functional consequences is of great clinical utility and is already helping to determine
phenotypic plasticity, histological tumour grading and overall prognosis and survival stratification in several cancer
types. As epigenetic changes - contrary to genetic changes - are potentially reversible, they may prove to be
potent therapeutic targets to add to the cancer physicians’ armorarium in the future.
Here, we review the therapeutic potential of epigenetic modifications (including DNA methylation, histone
modifications and miRNAs) occurring in hypoxia with particular reference to cancer and tumourigenesis.
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Introduction
Tumour hypoxia - a regulatory factor in tumour growth
Control of cellular oxygen concentration is under strict
regulation as hyperoxia causes damage secondary to reac-
tive oxygen species and hypoxia leads to activation of a
diverse array of downstream transcriptional pathways
including angiogenesis, glucose metabolism and apoptosis.
It is well understood that tumourigenesis is dependent
on the development of microvasculature for micronutrient
supply and oxygenation. As this vasculature develops in a
chaotic way with structural malformations, regions of
hypoxia are present within all solid tumours. Normal oxy-
gen tension in healthy tissue is 7% (53 mmHg), levels of
oxygenation in tumours may vary from physiological levels
(7%) to severe hypoxia (< 1%) which is usually found in
areas adjacent to necrotic tissue [1]. It has also been
reported that within the samer e g i o no fag i v e nt u m o u r ,
levels of oxygenation may cycle due to poor vasculature
and limited oxygen diffusion, resulting in intermittent per-
iods of hypoxia [1]. These cyclical episodes of hypoxia lead
to increased metastatic potential of cancer cells [2].
Cellular hypoxia is toxic, and when severe leads to cell
death in both normal and cancerous cells. However, can-
cer cells have developed mechanisms through (epi)genetic
modifications which allow them to survive and in some
cases thrive in hypoxic conditions [3]. Preclinical studies
have demonstrated that the selective pressure of tissue
hypoxia drives the selective outgrowth of more aggressive
tumour sub-clones [4]. In early stage lung cancer and pan-
creatic endocrine cancer markers of hypoxia have outper-
formed traditional histopathological staging for predicting
prognosis [5,6].
The direct observation of tumour hypoxia through oxy-
gen electrode recording was first made over ten years ago
[7]. This study demonstrated the relationship between low
oxygen tension and increased risk of metastasis along with
poor prognosis in head and neck, breast and cervical can-
cers. It has since been possible to demonstrate hypoxia in
vivo through the injection of pimidiazole [8].
The hypoxia inducible factor (HIF) pathway is the key
regulatory pathway activated in response to tissue
hypoxia. In normoxic conditions HIF is degraded
through interaction with the Von-Hippel Lindau (VHL)
tumour suppressor protein (pVHL) where it becomes
polyubiquinated and undergoes proteosomal degradation.
The interaction between VHL and HIF is controlled via
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prolyl hydroxylases (PHDs). In hypoxic conditions HIF
d o e sn o tb i n dt oV H Ld u et ot h ea c t i o no fP H D sa n d
therefore accumulates. HIF-1a then binds to hypoxia
response elements (HRE) along with co-factors HIF-1b
(also known as arylhydrocarbon receptor nuclear factor
(ARNT)), E1A binding protein p300 (EP300), jun proto-
oncogene (c-JUN) and cAMP responsive element binding
protein (CREB). This leads to the transcription and up-
regulation of over 100 genes involved in angiogenesis,
glucose metabolism and transportation, erythropoietin
production, cellular proliferation, tumour invasion/
metastasis and p53 mediated apoptosis [9,10]. Three
HIF-a subunits have been identified, HIF-1a and HIF-2a
are thought to have roles in acute and chronic hypoxia
respectively whereas the role of HIF-3a is yet to be deter-
mined [11]. In vitro studies in several cell culture systems
have shown that HIF is activated at approximately 5% O2
(40 mmHg) and activity increases with decreasing oxyge-
nation down to 0.2-1.0% (1.6-0.8 mmHg) O2 nearing
anoxia [12]. See Figure 1 for an overview of the HIF path-
way (adapted from Biocarta, http://www.biocarta.com).
As HIF activation leads to the development of tumour
vascularisation, it plays a significant role in tumour pro-
gression and metastasis. Over-expression of HIF-1a and
HIF-2a has been documented in several primary tumours
and associated metastases, the degree of expression cor-
relates with angiogenesis, resistance to treatment and
overall patient outcome [9,3]. The HIF pathway can also
be activated through germline or somatic mutation of
VHL or through VHL promoter methylation leading to
transcriptional repression. Renal cell carcinoma can
develop through all of these mechanisms (reviewed in
[13,14]). For a review of the role of HIF in tumourigen-
esis see [12,3,15]. As HIF activation can be deleterious to
both cancerous and normal cells, feedback mechanisms
exist to control the level of HIF activation, which leads to
as w i t c hf r o mH I F - 1 a to HIF-2a driven response when
acute hypoxia becomes chronic. HIF-2a driven responses
occurring in chronic hypoxia may be involved in the reg-
ulation of tumour cellular differentiation and stem cell
maintenance (reviewed in [16]).
Alongside HIF related transcriptional response to tissue
hypoxia, there is increasing evidence to support the devel-
opment of hypoxia mediated epigenetic modifications
which lead to further transcriptional changes and chromo-
somal instability. This is mediated through changes in
DNA methylation at promoter regions and satellite repeats
[17], histone modifications [18], and micro-RNAs [19].
Further genetic instability in hypoxia is due to gene ampli-
fication and DNA strand breaks at fragile sites alongside
disruption of DNA repair [20].
Phenotypic transition can also occur as a result of
hypoxia, with evidence of epithelial - mesenchymal
transition (EMT) [21] and the development of tumour
specific cancer stem cells (CSC), as seen in glioblastoma
[1] and breast cancer [22]. CSCs are phenotypically
similar to normal stem cells and behave similarly in that
they are able to up-regulate DNA repair enzymes [23].
Epigenetic manifestations of hypoxia in normal tissue
It is clear that the physiological response to hypoxia in
normal tissues and organs must involve epigenetic modifi-
cations which lead to downstream changes in gene expres-
sion which have either protective or adaptive functions.
The following studies have found evidence of a global
increase in DNA methylation following a period of
hypoxia with associated changes in transcriptional activa-
tion and repressive histone marks.
RNA expression array studies on murine placenta iden-
tified increased expression of DNA methyltransferase 3B
(Dnmt3b), and methyl-CpG binding domain protein 1
(Mbd1) following a 48 hour period of hypoxia [24]. An
increase in the expression of genes involved in metabo-
lism, oxygen transport, proteolysis, cell death and reactive
oxygen species metabolism was also identified. It was con-
cluded from this study that hypoxia may contribute to
long-term epigenetic changes in hypoxically stressed tis-
sues and organs. Previous studies have demonstrated that
reactive oxygen species can affect DNA methylation [25]
suggesting a mechanism for the increased expression of
DNA methyltransferases in hypoxia.
Increased expression of DNA methyltransferases during
hypoxia in human tissues was confirmed when Watson
et al determined the epigenetic signature of chronic
h y p o x i ai nn o r m a lp r o s t a t ec e l ll i n e s[ 2 6 ] .F o l l o w i n ga7
week period of normoxic culture, cells were then cultured
for a further 4 weeks at 3% O2 and then 3 weeks at 1% O2
prior to assessment of global DNA methylation, DNMT
and histone deacetylase activity. This found a global
increase in DNA methylation with concomitant increase
in DNMT3B expression and H3K9 histone acetylation.
Gene-specific changes in DNA methylation were also
observed at several key loci of imprinted genes.
Hypoxia is known to induce alterations in chromatin,
including global deacetylation and also changes in his-
tone methylation and acetylation in the promoter
regions of hypoxia related genes. Chromatin precipita-
tion analysis has identified a signature of chromatin
modifications which is induced
under hypoxic stress. It has been suggested that this may
play a role in gene regulation in proliferating tumour cells
undergoing cyclic periods of hypoxia [27].
The jumonji-domain containing dioxygenases (JMJD)
group of histone demethylases (JHDMs) have been
recently described and are found to be regulated in
hypoxic conditions through HIF-1a [28]. Within the
JMJD group, JMJD1A and JMJD2B were found to be
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showing modest up-regulation. This hypoxia related
dynamic control of histone methylation is thought to reg-
ulate chromatin assembly and gene expression. JMJDs
affect gene expression through demethylation of lysine
residues of histone tails. In particular, JMJD1A has been
found to demethylate H3K9me1 and H3K9me2 and
JMJD2B demethylates H3K9me3. Transcriptional path-
ways have also been associated with individual JMJDs,
JMJD1A is associated with the androgen receptor (AR)
and regulates AR target genes. Both JMJD1A and
JMJD2C regulate and increase the expression of genes
involved in self-renewal and are targets for the transcrip-
tion factor Oct-4 in embryonic stem cells[28].
Although all of these studies have documented a global
increase in DNA methylation and histone modifications,
which are associated with changes in downstream tran-
scription, there are no studies to date which document the
time course or order of these events. It is very likely that
different cell and tissue types would require varying peri-
ods of hypoxia before “normal” hypoxic cells become “pre-
cancerous” or “cancerous” hypoxic cells.
Epigenetic manifestations of hypoxia in tumour
development
DNA methylation
The observation of global hypomethylation was first
observed in colorectal cancer cell lines in the 1980’s [29].
Over the following twenty years a number of tumour
suppressor genes were found to be silenced through pro-
moter region hypermethylation [30]. The first DNA
methylome (at single nucleotide resolution) was pub-
lished in 2008, this was followed in quick succession by
several other studies which have given us a wealth of
information regarding the function of DNA methylation
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Figure 1 Overview of the hypoxia inducible factor (HIF) pathway. In normoxic conditions, HIF-1a binds to VHL at specific proline residues
leading to ubiquitination and proteosomal degradation. During hypoxia, HIF-1a no longer binds to VHL and accumulates. This leads to
formation of the hypoxia response element and subsequent transcription (HIF-1b also known as ARNT (aryl hydrocarbon receptor nuclear
translocator), cJUN - jun proto-oncogene, CREB - cAMP responsive element binding protein 1, EP300 - E1A binding protein p300).
Thirlwell et al. Clinical Epigenetics 2011, 3:9
http://www.clinicalepigeneticsjournal.com/content/3/1/9
Page 3 of 9[31]. For example, the concept of CpG island shores was
developed (regions of lower CpG density occurring
within 2 kb of CpG islands) [32]. These regions have
since been found to harbour the majority of tissue speci-
fic differentially methylated regions of DNA [33].
There are few studies which have investigated genome-
wide DNA methylation changes occuring during hypoxia.
Methylation within DNA repeat elements (retrotranspo-
sable Alu and other short interspersed nuclear elements
(SINEs)) is known to contribute to genomic stability, it
has been postulated that chronic hypoxia can lead to glo-
bal hypomethylation and subsequent increase in genomic
instability and aneuploidy which is often observed in
tumourigenesis. This is supported by two studies [17,34]
reporting an increase in global hypomethylation in glio-
blastoma, sarcoma, colorectal cancer and melanoma cell
lines when cultured in hypoxic conditions when com-
pared to normoxic culture. The study of glioblastoma
and sarcoma cell lines used RT-PCR methodology along-
side bisulphite sequencing of Alu and other SINE repeat
regions within the genome, whereas the study of colorec-
tal cancer and melanoma cell lines used HPLC to quan-
tify 5-methylcytosine (5-mC). These findings are the
exact opposite of those observed when culturing non-
cancerous cells in hypoxic conditions (ie an increase in
global methylation) and may in part be due to a break-
down in the feedback mechanisms which exist to control
the degree of HIF activation occurring in cancer cells and
not normal cells during hypoxia.
Histone modifications
The most common histone modifications occurring in can-
cer are acetylation, deacetylation or methylation at lysine
residues. These modifications are catalysed by histone dea-
cetylases (HDACs) and histone methyltranferases (HMTs)
[35]. Histone acetylation is most commonly associated with
repression of transcription, whereas histone methylation is
associated with both transcriptional activation and repres-
sion. A number of methylation reactions are associated
with transcriptional activity (di- and trimethylation of
H3K4 (H3K4me2 and H3K4me3), trimethylation of H3K36
(H3K36me3) and dimethylation of H3K79 (H3K79me2). In
contrast, di- and trimethylation at H3K9, H3K27 and
H4K20 is associated with gene silencing [36,37]. Specifically
in cancer, a global loss of H4K16ac is seen alongside loss of
the transcriptionally active mark H3K4me3 and gain of the
transcriptionally repressive marks H3K9me and H3K27me
[38].
Histone modifying enzymes play a key role in hypoxia-
related tumourigenesis It is increasingly evident that his-
tone modifying enzymes play a key role in hypoxia-
related tumourigenesis. Several research groups have
demonstrated that hypoxia regulates the activity of his-
tone demethylases [18]. Xia et al used ChIP-chip and
RNA expression profiling of HepG2 (hepatocellular
cancer cell line) and U87 (glioma cell line) cells grown in
normoxic (ambient) and hypoxic (0.5% O2 for 4 hours)
conditions to define HIF-1 chromatin binding targets. In
total, 377 HIF-1 binding sites activated by hypoxia were
identified across the genome. As predicted, many of the
genes associated with these binding sites were from bio-
logical pathways known to be activated and controlled by
HIF. However, enrichment for the 2-oxoglutarate dioxy-
genase family of enzymes was also observed including the
previously described JHDMs. It was further demonstrated
that up-regulation of these JHDMs helps to maintain his-
tone homeostasis during hypoxic tumorigenesis [18]. The
JHDM family of histone demethylases do not only require
oxygen to function but are in some cases induced during
hypoxia through HIF related mechanisms [11]. The
JHDMs, JMJD2B and JMJD2C have been found to have
oncogene-like propertied and are amplified in squamous
cell of the oesophagus and medulloblastoma [39,40].
In addition, inactivating mutations in enzymes control-
ling histone modification have been detected in clear cell
renal carcinoma (ccRCC), clear cell ovarian cancer [41]
and pancreatic neuroendocrine tumours [42]. The histone
modifying enzymes directly involved in ccRCC develop-
ment are SET domain containing 2 (SETD2), a histone H3
lysine 36 methyltransferase, Jumonji/ARID domain-con-
taining protein 1C (JARID1C),ah i s t o n eH 3l y s i n e4
demethylase and ubiquitously transcribed X chromosome
tetratricopeptide repeat protein (UTX) a histone H3 lysine
27 demethylase [43,44]. Even though a small fraction of
clear cell renal cell carcinoma (3%) cases harboured inacti-
vating mutations in SETD2 or JARID1C, these mutations
are potentially of high relevance in hypoxia since 88% of
samples with SETD2 and JARID1C inactivating mutations
also harboured mutations in VHL and/or over-expression
of egl nine homolog 3 (ELGN3) which is also known as
HIF-prolyl hydroxylase 3 (PHD3) [43]. JARID1B, a histone
H3 lysine 4 demethylase is found to be up-regulated in
prostate cancer [45].
In gastric cancer, a hypoxia-induced epigenetic silen-
cing of the tumour suppressor RUNX3 through histone
H3-lysine 9 dimethylation and decreased H3 acetylation
during disease progression has been observed [46].
RUNX3 is also known to be silenced in several cancers
through promoter methylation. This study performed on
gastric cancer cell lines revealed that following treatment
with the histone deacetylase inhibitor trichostatin A and
the cytosine-methylation inhibitor 5-aza-2-deoxycytidine,
down-regulation of RUNX3 was reversed. Bisulphite-spe-
cific PCR demonstrated that promoter region methyla-
tion was unchanged in hypoxia, whereas chromatin
immunoprecipitation (CHIP) found an increase in the
repressive histone mark H3K9me2 and a decrease in the
transcriptionally active H3K9 acetylation mark. It was
also found that the G9a histone methyltransferase and
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diminished nuclear localisation and expression of
RUNX3, demonstrating an epigenetic mechanism for the
observed decrease in RUNX3 expression.
Hypoxic induction of histone demethylases therefore
play a pivotal role in tumourigenesis, one such mechanism
being HIF- a mediated induction of JHDMs leading to
cancer progression. The role of histone methyltransferases
which may oppose the effects of histone demethylases dur-
ing hypoxia is less well understood. If the effects of these
two opposing families of histone modifying enzymes dur-
ing hypoxia are determined, a vital connection between
environmental stressors and epigentically regulated
tumourigenesis would be made and furthermore, novel
epigenetic cancer therapeutic targets identified.
Micro-RNAs
Micro-RNAs (miRNAs) are short (20-24) non-coding
nucleotide RNA molecules [47]. They are thought to regu-
late gene expression through control of mRNA turnover,
inhibition of translation, promoter region activation and
epigenetic silencing [48]. The “micro-transcriptome” is
thought to account for 1-2% of the human genome and
regulate the majority of translated genes [49]. miRNAs
have the ability to “respond” both immediately and reversi-
bly to hypoxic stress. miRNAs identified and implicated in
tumorigenesis when normal tissue and tumour samples
are compared [50] are affected through several factors in
the tumour microenvironment such as hypoxia, pH, glu-
cose metabolism and paracrine growth factors. Hypoxia
regulated miRNAs are implicated in both renal cell cancer
an glioblastoma development, several other hypoxia regu-
lated miRNAs are in development and cancer bioamar-
kers, these are discussed below.
Hypoxia related mi-RNAs can be used as diagnostic
and prognostic cancer biomarkers Kulshreshtha et al
have identified a group of hypoxia regulated miRNAs
(HRMs). Several of these miRNAs regulate apoptotic sig-
nalling during hypoxic periods. The majority of the identi-
fied HRMs were found to be over-expressed in human
cancers and were consistently induced in breast and color-
ectal cancer cell lines during culture in hypoxic conditions
[51,52]. Other groups have also reported induction of
miRNAs as a response to hypoxia [53] but it is difficult to
compare studies directly due to variation in culture times
and degree of hypoxia used for culturing between research
groups.
miR-210 is known to be regulated by hypoxia and has
found to be a diagnostic marker in pancreatic adenocarci-
noma [54] and prognostic marker in breast cancer [55].
miR-210 is also over-expressed in late stage non-small cell
lung cancer [56]. Subsequent in vitro studies on the lung
adenocarcinoma cell line A549 demonstrated that miR-
210 expression results in caspase 3/7 activity, followed by
mitochondrial dysfunction. In the same study, subunit D
of succinate dehydrogenase complex (SDHD) was vali-
dated as a miR-210 target [56].
The relationship between the HIF pathway and
hypoxia-mediated miRNAs Neal et al first demon-
strated the impact of the VHL tumour suppressor gene
on miRNAs in renal clear cell carcinoma [57]. This study
elegantly showed that miRNAs are downstream effectors
of the HIF-induced hypoxia response. Under hypoxic
conditions (or through VHL mutation or VHL promoter
methylation), miR-210 expression is significantly
increased and potentially targets the iron-sulphur cluster
protein (ISCU). ISCU is implicated in the mitochondrial
electron transport chain and potentially, in anaerobic
respiration of tumours. A further group of miRNAs has
been identified which regulate VEGF (miR-16, 20a, 20b,
17-5p, 27a, 106a, 106b, 107, 193a, 210, 320, 321) [58].
The over expression of miR-21 (a HRM) has been impli-
cated in the development of glioblastoma (which is known
to have extensive regions of hypoxia and necrosis), and
knock-down of this miRNA in glioblastoma cell lines lead
to apoptosis, suggesting a role in tumour survival [59].
Although none of the hypoxia regulated miRNAs
described above are used routinely for clinical diagnosis
and prognosis to date, these biomarkers once validated,
are easily accessible from both tissue biopsies, resections
and are found in circulating plasma enabling clinical
access for both diagnostic and prognostic purposes.
Potential epigenetic targets for hypoxia related cancer
therapy
DNA methyltransferase inhibitors
DNA methyltransferase (DMNT) inhibitors have been
investigated for some years as a novel class of anti-cancer
drug. There is substantial evidence to support the use of
the DNMT inhibitors 5-azacytidine and 5-aza-2’-deoxycy-
tidine (decitabine) for certain haematological malignancies,
resulting in their approval by the FDA. Following a num-
ber of phase I and II trials the evidence for their use in
solid tumours is less encouraging. In light of this, these
agents have not been trialled with specific reference to
tumour hypoxia. Treatment with decitabine has been
shown to lead to re-expression of VHL in clear cell renal
carcinoma in vitro and in vivo through inhibition of DNA
methylation in the VHL promoter region [60]. This leads
to restoration of the normal physiological HIF pathway
and reduction of accumulation of HIF-1a and down-
stream hypoxia response element related transcription.
Re-expression of BNIP3 which is associated with hypoxia
mediated apoptosis following treatment with decitabine
has also been observed in pancreatic adenocarcioma cell
lines [61].
Histone Deacetylase Inhibitors
HDAC inhibitors are compounds which function through
inhibition of deacetylases, they are a diverse group of
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inhibitors do not act solely as inhibitors of HDACs as a
large number of non-histone transcription factors and
transcriptional co-regulators are known to be modified
by acetylation.
A clear mechanism of action of these drugs is yet to be
elucidated. To date, they have been found to have pro-
apoptopic and anti-angiogenic properties. Several HDAC
inhibitors are currently under evaluation in clinical trials
both a single agents and in combination with chemother-
apry and targeted therapy [62-64]. The second generation
HDAC inhibitor Vorinostat has been approved by the
FDA for the treatment of cutaneous T cell lymphoma.
Recently it has been shown that the class I and II
HDAC inhibitors disrupt HIF both directly through
reduction of HIF-1a levels and indirectly through repres-
sing transcription, the exact mechanism of this remains
unknown [65]. A number of HDAC inhibitors have been
reported to down-regulate HIF-1a stability in cancer cell
lines. It has been suggested that the transcription com-
plexes of HIF-1a and HIF-2a require modification by
type I/II deacetylases in order to become transcriptionally
active, it is through this mechanism that HDAC inhibi-
tors are thought to reduce HIFt r a n s c r i p t i o n[ 6 6 ] .F a t h
et al further demonstrated that the inhibition of HIF-1a
and HIF-2a transactivation mediated by HDAC inhibi-
tors was independent of VHL and p53 function. This is a
significant finding as it implies that HDAC inhibitors
may have a therapeutic effect in VHL deficient tumours
(such a renal cell cancer and pancreatic neuroendocrine
tumours). The class III HDAC inhibitor SirtI has also
been found to deacetylate HIF-1a and HIF-2a thus
repressing HIF activity [67].
Sodium butyrate, a novel HDAC inhibitor has been
shown to inhibit hypoxia induced HIF1a induction and
inhibited in vitro and in vivo angiogenesis [68]. The study
demonstrated that sodium buyrate treatment of endothe-
lial cells down-regulated both HIF1a and VEGF protein
levels thereby regulating angiogenesis. This indicates that
HDACs are involved in oxygen dependant gene expression
and angiogenesis.
Combination of HDAC inhibitors with other targeted
treatments can have an additive effect Verheul et al.,
demonstrated in prostate and renal cancer cell lines that
combination treatment with the mTOR inhibitor rapamy-
cin and the HDAC inhibitor LBH589, significantly reduced
HIF-1a protein expression and consequently suppressed
tumour induced angiogenesis on comparison with either
agent used singularly [69].
The effects of HDAC inhibitors on both HIF degrada-
tion and transcription are therapeutically very appealing
and further clinical evaluation should be considered trial-
ing other targeted treatments such as mTOR and VEGF
inhibitors alongside HDAC inhibition. It should be noted
however that long term systemic administration of
HDAC inhibitors may lead to downstream effects on ery-
thropoeisis and ischaemia (including coronary ischaemia)
through inhibition of the physiological role that HIF
plays in erythoropoietin production, and adaptive meta-
bolic changes that occur during hypoxia. Therefore sche-
duling and timing of these therapies requires robust
phase I trial assessment.
mi-RNA targeted therapy
Through the identification of specific miRNAs involved in
tumorigenesis (in both normoxic and hypoxic conditions)
it is deemed feasible to inhibit specific miRNAs in the
future through anti-miRNA oligonucleotides [70], locked
nucleic acid-modified oligonucleotides [71] and antago-
mirs [72]. To date, none of these agents have progressed
further than phase I clinical trials.
There is recent evidence supporting the potential use of
anti-oxidants and naturally occurring compounds to regu-
late miRNA expression in cancer cells [73]. Li et al [74]
demonstrated down-regulation of miR-135a and miRNA
135b in colorectal cancer cell lines (which target the 3’
untranslated region of adenomatous polyposis coli gene)
through treatment with mistletoe lectin-I, the mechanism
of this is thought to be through degradation of the miRNA
precursors. Anti-oxidants such as Se-Methylselenocysteine
(MSC) and N-acetyl cysteine (NAC) have been shown to
inhibit HIF-1a in solid tumours in mouse models [75,76],
historically it was thought that anti-oxidants had an anti-
tumourigenic effect through the reduction of reactive oxy-
gen species (ROS) and subsequent DNA damage, these
studies demonstrate a direct inhibition of HIF by anit-oxi-
dants. MSC when administered alongside irinotecan che-
motherapy improved clinical outcome in mice with
human squamous cell tumour xenografts through inhibi-
tion of HIF-1a [75] and NAC was shown to reduce HIF
activity in mouse models of hepatocellular carcinoma and
B cell lymphoma [76].
The role of miR-210 in relation to tumour hypoxia has
been recently reviewed [77]. Alongside its potential use as
a novel hypoxia diagnostic marker in pancreatic cancer
[54,78] and prognostic biomarker in breast [55], head and
neck [79] and renal cancer [57]. Although these studies do
n o td e m o n s t r a t ead i r e c tm i - R N At a r g e t e dt h e r a p y ,t h e y
illustrate a novel potential of these epigenetic markers
within a clinical setting to help aid cancer diagnosis via
non-invasive methods and ultimately impact on patient
treatment and prognosis. Table 1 gives an overview of
tumourigenic hypoxia related epigenetic changes and
potential therapeutic strategies and targets.
Conclusions and outlook
It is clear that epigenetic changes occurring during
hypoxia have a significant downstream effect physiologi-
cally in normal tissue, in the transition from normal to
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These changes can be used as biomarkers in diagnosis
and prognosis, for example the micro-RNA miR-210 in
pancreatic and breast cancer.
However, in order to fully understand these changes
and harness their clinical benefit for diagnostics and
therapeutics, several key areas need to be addressed
which are discussed below.
In normal tissue global DNA hypermethylation is
observed following a period of hypoxia whereas in cancer
cell lines global DNA hypomethylation is observed leading
to increased genomic instability. This is likely due to
decreased DNA methyltransferase activity - both mainte-
nance and de novo. What we do not know is whether the
global DNA hypomethylation observed in hypoxic cancer
tissue is somehow protective enabling survival in hypoxic
conditions.
It is not known whether a stepwise chain of epigenetic
events occurs during hypoxia, ie changes in DNA methyla-
tion occurring before histone modifications and alteration
in expression of downstream mi-RNAs. If this sequence of
events could be determined it might highlight the best
diagnostic and therapeutic strategies to employ in different
cancer types. In reality it is likely that there is interaction
and positive and negative feedback between all epigenetic
modifications.
Therapeutically, DNMT inhibitors have not been trialled
with respect to tumour hypoxia. However HDAC inhibi-
tors appear to have a direct effect on both HIF transcrip-
tion and degradation making them promising therapeutic
agents for use in vascular tumours and tumours with
severe regions of hypoxia. If used in the right clinical set-
ting for selected tumour types this therapeutic interven-
tion could prove to be clinically beneficial. Future
therapeutic strategies could include the integration of
HDAC inhibition with other targeted therapies such
mTOR and VEGF/c-kit/platelet derived growth factor
(PDGF) tyrosine kinase inhibitors. Sequencing and
duration of treatment with such therapies in combination
is yet to be determined.
With the recent massive expansion of molecular biol-
ogy tools available for studying the epigenome (both
array and sequencing based) [80], we are at a turning
point in furthering our understanding of the effects of
hypoxia on the epigenome and identifying novel clinical
biomarkers and therapeutic targets.
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